Russell Z Szmulewitz
Overview
Explore the profile of Russell Z Szmulewitz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
1847
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cho Y, Karrison T, Jack M, Choksi A, Knoebel R, Yeo K, et al.
J Pain Res
. 2024 Dec;
17:4187-4196.
PMID: 39717756
Background: Cancer patients frequently suffer from pain, often managed with opioids. However, undertreated pain remains a significant concern. Opioid effectiveness varies due to genetic differences in how individuals metabolize some...
2.
Chernoff M, Demanelis K, Gillard M, Delgado D, Gleason K, Oliva M, et al.
Cancer Epidemiol Biomarkers Prev
. 2024 Dec;
34(3):428-438.
PMID: 39699292
Background: African American (AA) men are at increased risk of prostate cancer compared with European American (EA) men. Biological mechanisms, including epigenetics, likely contribute to this disparity, but prior studies...
3.
Huang D, Lynch C, Serra L, Sweis R, Chang P, Stadler W, et al.
Clin Transl Radiat Oncol
. 2024 Nov;
49:100879.
PMID: 39529961
Background And Purpose: Stereotactic ablative body radiotherapy (SABR) is an effective treatment for localized renal cell carcinoma (RCC). However, the role of primary site SABR for locally recurrent or metastatic...
4.
Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller C, et al.
Clin Cancer Res
. 2024 Aug;
30(19):4318-4328.
PMID: 39115414
Purpose: Deleterious germline/somatic homologous recombination repair mutations (HRRm) are present in ∼25% of patients with metastatic castration-resistant prostate cancer (mCRPC). Preclinically, poly(ADP-ribose) polymerase (PARP) inhibition demonstrated synergism with androgen receptor...
5.
Rajeev-Kumar G, Pitroda S, Szmulewitz R, Skolarus T, Eggener S, Liauw S
Clin Genitourin Cancer
. 2024 May;
22(4):102103.
PMID: 38781786
Background: We previously reported that for men undergoing combined androgen deprivation therapy (ADT) and radiation therapy (RT) for prostate cancer, substitution of LHRH-agonists with 5-α- reductase inhibitors (5-ARIs) led to...
6.
Desai K, Serritella A, Stadler W, ODonnell P, Sweis R, Szmulewitz R
Clin Cancer Res
. 2024 Mar;
30(11):2384-2392.
PMID: 38536082
Purpose: The majority of patients with metastatic prostate cancer who receive androgen-deprivation therapy and androgen receptor (AR) signaling inhibitors (ARSI) progress. Activation of the glucocorticoid receptor (GR) is associated with...
7.
Lynch C, Sweis R, Modi P, Agarwal P, Szmulewitz R, Stadler W, et al.
Clin Genitourin Cancer
. 2024 Jan;
22(2):476-482.e1.
PMID: 38228414
Introduction: Many patients with muscle-invasive bladder cancer are poor candidates for radical cystectomy or trimodality therapy with maximal transurethral resection of bladder tumor (TURBT) and chemoradiotherapy with cisplatin or mitomycin...
8.
Gomez-Veiga F, Szmulewitz R, Holzbeierlein J, Azad A, Iguchi T, Villers A, et al.
Eur Urol Oncol
. 2023 Dec;
7(4):860-869.
PMID: 38072761
Background: In ARCHES, treatment intensification of androgen deprivation therapy (ADT) with enzalutamide versus placebo improved clinical outcomes in metastatic hormone-sensitive prostate cancer (mHSPC). Understanding the benefits and tolerability of enzalutamide...
9.
Bennett L, Jaiswal P, Harkless R, Long T, Gao N, Vandenburg B, et al.
Mol Cancer Ther
. 2023 Nov;
23(4):552-563.
PMID: 38030378
In castration-resistant prostate cancer (CRPC), increased glucocorticoid receptor (GR) expression and ensuing transcriptional activity have been proposed as an oncogenic "bypass" mechanism in response to androgen receptor (AR) signaling inhibition...
10.
Meier J, Zhang H, Freifelder R, Bhuiyan M, Selman P, Mendez M, et al.
Molecules
. 2023 Aug;
28(16).
PMID: 37630292
In the field of nuclear medicine, the β -emitting Sc and β -emitting Sc are promising candidates in cancer diagnosis and targeted radionuclide therapy (TRT) due to their favorable decay...